After hosting meetings with TherapeuticsMD (TXMD), Stifel analyst Annabel Samimy said she maintains her bullish stance and reiterated a Buy rating on the stock with a $20 price target. Imvexxy "finally" got commercial coverage at CVS (CVS), Bijuva was added at Cigna (CI), and Annovera distribution begins with 40% unrestricted coverage, noted Samimy, who sees the company being on track to meet its 2019 guidance and "see rapid growth from this point forward. Additionally, a survey produced "multiple favorable signals for future uptake," leaving her increasingly confident that TherapeuticsMD can reach a leadership position in Women's Health, said Samimy.